foxo4 dri human trial senolytic The disordered p53 transactivation domain is the target of and the compound FOXO4-DRI FOXO4-DRI 10mg vial - Description
FOXO4 DRI 10mg vial Description RCpeptides FOXO4 DRI alleviates age related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Aging FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology TRANSLATING THE BIOLOGY OF AGING INTO NEW THERAPEUTICS FOR ALZHEIMER'S DISEASE: SENOLYTICS The Journal of Prevention of Alzheimer's Disease
Pay in 4 interest-free payments of $6.47 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 17 - Sep 22


